Researchers reported progress toward in vivo CAR-neutrophil engineering as a potential new modality for glioma treatment. The approach centers on direct genetic programming of neutrophils—an area that has historically been difficult because of technical barriers to modifying the cells. The development aims to leverage neutrophils’ abundance and their role in the tumor microenvironment, converting them into targeted anti-tumor effectors via CAR constructs. For glioblastoma and other glioma subtypes, the field continues to search for cell therapies that can overcome delivery and persistence constraints. While the details provided focus on the technical advance rather than trial outcomes, it marks a step toward broader applicability of cell-based immunotherapies in CNS oncology.